Measurement of Residual Cancer Burden in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy and Correlation with Biomarker Expression and Molecular Subtypes

被引：0
|
作者：
Cockburn, A. [1 ]
Peng, Y. [1 ]
Euhus, D. [1 ]
Haley, B. [1 ]
Sarode, V. [1 ]
机构：
[1] Univ Texas SW, Dallas, TX USA
来源：
MODERN PATHOLOGY | 2011年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
129
引用
收藏
页码：33A / 33A
页数：1
相关论文
共 50 条
  • [31] Residual cancer burden (RCB) in breast cancer patients treated with taxane- and anthracycline-based neoadjuvant chemotherapy: The effect of race.
    Chavez-Mac Gregor, M.
    Hubbard, R.
    Meric-Bernstam, F.
    Shinde, S. S.
    Litton, J. K.
    Woodward, W. A.
    Valero, V.
    Hortobagyi, G. N.
    Symmans, W. F.
    Gonzalez-Anguio, A. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [32] Chemosensitivity to Neoadjuvant Chemotherapy of Breast Cancer Subtypes
    Lee, J. S.
    Kim, J. R.
    Chang, E. S.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S350 - S350
  • [33] The accuracy of MRI in estimating residual tumour in the breast after neoadjuvant chemotherapy for early breast cancer patients according to each molecular subtypes
    Ichikawa, M.
    Hattori, M.
    Fujita, T.
    Sawaki, M.
    Kondo, N.
    Horio, A.
    Gondo, N.
    Idota, A. I.
    Iwata, H.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : S64 - S64
  • [34] Residual cancer burden index and tumor-infiltrating lymphocyte subtypes in triple-negative breast cancer after neoadjuvant chemotherapy
    Clémence Pinard
    Marc Debled
    Houda Ben Rejeb
    Valérie Velasco
    Christine Tunon de Lara
    Stéphanie Hoppe
    Elodie Richard
    Véronique Brouste
    Hervé Bonnefoi
    Gaëtan MacGrogan
    Breast Cancer Research and Treatment, 2020, 179 : 11 - 23
  • [35] Residual cancer burden index and tumor-infiltrating lymphocyte subtypes in triple-negative breast cancer after neoadjuvant chemotherapy
    Pinard, Clemence
    Debled, Marc
    Ben Rejeb, Houda
    Velasco, Valerie
    Tunon de Lara, Christine
    Hoppe, Stephanie
    Richard, Elodie
    Brouste, Veronique
    Bonnefoi, Herve
    MacGrogan, Gaetan
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 179 (01) : 11 - 23
  • [36] Impact of Molecular Subtypes and Pathologic Response on Locoregional Recurrence (LRR) and Survival in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy
    Kubicky, C. Dai
    Mongoue-Tchokote, S.
    Chui, S.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S258 - S258
  • [37] Comparison of Tumor Biomarker Expression in Breast Cancer Patients before and after Neoadjuvant Chemotherapy
    Cockburn, A.
    Fang, Y.
    Peng, Y.
    Haley, B.
    Sarode, V.
    LABORATORY INVESTIGATION, 2011, 91 : 34A - 34A
  • [38] Comparison of Tumor Biomarker Expression in Breast Cancer Patients before and after Neoadjuvant Chemotherapy
    Cockburn, A.
    Fang, Y.
    Peng, Y.
    Haley, B.
    Sarode, V.
    MODERN PATHOLOGY, 2011, 24 : 34A - 34A
  • [39] The residual cancer burden index as a valid prognostic indicator in breast cancer after neoadjuvant chemotherapy
    Xu, Xin
    Zhao, Wei
    Liu, Cuicui
    Gao, Yongsheng
    Chen, Dawei
    Wu, Meng
    Li, Chao
    Wang, Xinzhao
    Song, Xiang
    Yu, Jinming
    Liu, Zhaoyun
    Yu, Zhiyong
    BMC CANCER, 2024, 24 (01)
  • [40] Residual cancer burden and neoangiogenesis after neoadjuvant chemotherapy in triple-negative breast cancer
    Miyashita, M.
    Sasano, H.
    Tamaki, K.
    Hirakawa, H.
    Ishida, T.
    Ohuchi, N.
    BREAST, 2017, 32 : S100 - S101
12345